Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7577952rdf:typepubmed:Citationlld:pubmed
pubmed-article:7577952lifeskim:mentionsumls-concept:C0024660lld:lifeskim
pubmed-article:7577952lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:7577952lifeskim:mentionsumls-concept:C0814023lld:lifeskim
pubmed-article:7577952lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:7577952lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:7577952lifeskim:mentionsumls-concept:C0174725lld:lifeskim
pubmed-article:7577952pubmed:issue41lld:pubmed
pubmed-article:7577952pubmed:dateCreated1995-12-14lld:pubmed
pubmed-article:7577952pubmed:abstractTextMonoiodotyrosine margatoxin ([125I]MgTX) specifically and reversibly labels a maximum of 0.8 pmol of sites/mg of protein in purified rat brain synaptic plasma membrane vesicles with a dissociation constant of 0.1 pM under equilibrium binding conditions. This Kd value was confirmed by kinetic experiments (Kd of 0.07 pM), competition assays employing native margatoxin (MgTX) (Ki of 0.15 pM), and receptor saturation studies (Kd of 0.18 pM). Thus, this toxin represents the highest affinity, reversible radioligand for any membrane-bound receptor or ion channel described to date. [125I]MgTX binding in this system is modulated by charybdotoxin (Ki of 5 pM), kaliotoxin (Ki of 1.5 pM), and the agitoxins I and II (Ki's of 0.1 and 0.3 pM, respectively), in a noncompetitive manner. Moreover, alpha-dendrotoxin displayed a Ki value of 0.5 pM. Iberiotoxin was without any effect, suggesting that the receptor site is likely to be associated with a voltage-gated K+ channel complex. [125I]MgTX binding is inhibited by cations that are established blockers of voltage-dependent K+ channels (Ba2+, Ca2+, Cs+). The monovalent cations Na+ and K+ stimulate binding at low concentrations before producing complete inhibition as their concentrations are increased. Stimulation of binding results from an allosteric interaction that decreases Kd, whereas inhibition is due to an ionic strength effect. Affinity labeling of the binding site in rat brain synaptic plasma membranes employing [125I]MgTX and the bifunctional cross-linking reagent, disuccinimidyl suberate, causes specific and covalent incorporation of toxin into a glycoprotein of an apparent molecular weight (M(r)) of 74,000. Deglycosylation studies reveal an M(r) for the core polypeptide of the MgTX receptor of 63,000.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:7577952pubmed:languageenglld:pubmed
pubmed-article:7577952pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577952pubmed:citationSubsetIMlld:pubmed
pubmed-article:7577952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577952pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7577952pubmed:statusMEDLINElld:pubmed
pubmed-article:7577952pubmed:monthOctlld:pubmed
pubmed-article:7577952pubmed:issn0006-2960lld:pubmed
pubmed-article:7577952pubmed:authorpubmed-author:KaczorowskiG...lld:pubmed
pubmed-article:7577952pubmed:authorpubmed-author:GarciaM LMLlld:pubmed
pubmed-article:7577952pubmed:authorpubmed-author:EberhartAAlld:pubmed
pubmed-article:7577952pubmed:authorpubmed-author:SlaughterR...lld:pubmed
pubmed-article:7577952pubmed:authorpubmed-author:KnausH GHGlld:pubmed
pubmed-article:7577952pubmed:authorpubmed-author:KochR OROlld:pubmed
pubmed-article:7577952pubmed:issnTypePrintlld:pubmed
pubmed-article:7577952pubmed:day17lld:pubmed
pubmed-article:7577952pubmed:volume34lld:pubmed
pubmed-article:7577952pubmed:ownerNLMlld:pubmed
pubmed-article:7577952pubmed:authorsCompleteYlld:pubmed
pubmed-article:7577952pubmed:pagination13627-34lld:pubmed
pubmed-article:7577952pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:meshHeadingpubmed-meshheading:7577952-...lld:pubmed
pubmed-article:7577952pubmed:year1995lld:pubmed
pubmed-article:7577952pubmed:articleTitle[125I]margatoxin, an extraordinarily high affinity ligand for voltage-gated potassium channels in mammalian brain.lld:pubmed
pubmed-article:7577952pubmed:affiliationInstitute for Biochemical Pharmacology, Innsbruck, Austria.lld:pubmed
pubmed-article:7577952pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7577952pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7577952lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7577952lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7577952lld:pubmed